Skip to main content

Implementation of Fully Automated BOND RX Protocol for NanoString's GeoMx Assay

CONTACT YOUR RESEARCH EXPERT

To enhance both throughput and reproducibility, Leica Biosystems and NanoString have developed automated sample processing workflows for RNA. In this webinar, we will show you how the integrated workflows of the BOND RX and the Digital Spatial Profiler (DSP) can advance your translational research.

If you have viewed this educational webinar or training and would like to apply for continuing education credits with your certifying organization, please download the form to assist you in adding self-reported educational credits to your transcript.

Learning Objectives

Characterization of the spatial distribution and abundance of proteins and mRNAs with morphological context within tissues enables a better understanding of biological systems in many research areas, including immunology, oncology and neuropathology.

Analysis of samples across multiple tumor types and diseases has revealed novel spatially distinct protein and mRNA candidate biomarkers. However, it has proven difficult to perform such studies in a highly multiplexed manner at a throughput scale that is required for translational research programs. To address this unmet need, Leica Biosystems and NanoString have developed a novel platform that can perform high-plex analysis of proteins or mRNAs on a single FFPE section from distinct tissue spatial regions utilizing GeoMx® Digital Spatial Profiler (DSP). 

In this webinar you will be able to learn more about:

  • The integration of BOND RX into the GeoMx DSP workflow to automate translational research sample processing
  • Adoption and integration of the system at LabCorp
  • Technology benefit from a real user experience and comparison to manual system

For Research Use Only.

Leica Biosystems content is subject to the Leica Biosystems website terms of use, available at: Legal Notice. The content, including webinars, training presentations and related materials is intended to provide general information regarding particular subjects of interest to health care professionals and is not intended to be, and should not be construed as, medical, regulatory or legal advice. The views and opinions expressed in any third-party content reflect the personal views and opinions of the speaker(s)/author(s) and do not necessarily represent or reflect the views or opinions of Leica Biosystems, its employees or agents. Any links contained in the content which provides access to third party resources or content is provided for convenience only.

For the use of any product, the applicable product documentation, including information guides, inserts and operation manuals should be consulted.

Copyright © 2024 Leica Biosystems division of Leica Microsystems, Inc. and its Leica Biosystems affiliates. All rights reserved. LEICA and the Leica Logo are registered trademarks of Leica Microsystems IR GmbH.

About the presenter

Carlee Hemphill is a Lead Scientist I at the Covance CDx laboratory in RTP, NC with a background in histology, anatomical pathology and bioinformatics. Her current role is the development of IHC or multiplex immuno florescence assays, or computational pathology algorithms, for clients interested in a complementary or companion diagnostic testing assay for their immuo-oncology pharmaceutical drug development pipeline.